Inicio
Resultado de la búsqueda
1 búsqueda de la palabra clave 'haploidentical hematopoietic stem cell transplantation'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide / Marcos Arango Barrientos ; Juan Felipe Combariza Vallejo
Título : Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide Tipo de documento : documento electrónico Autores : Marcos Arango Barrientos, ; Juan Felipe Combariza Vallejo, Fecha de publicación : 2017 Títulos uniformes : Hematology/Oncology and Stem Cell Therapy Idioma : Inglés (eng) Palabras clave : Cyclophosphamide fever haploidentical hematopoietic stem cell transplantation peripheral blood stem cell transplantation prognosis Resumen : Objective/background: Noninfection-related fever can occur after peripheral blood stem cell infusion in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. The objective of this study was to analyze the incidence of fever and characterize some clinical features of affected patients. Methods: A retrospective case-series study with 40 patients who received haploidentical hematopoietic stem cell transplantation was carried out. Results Thirty-three patients (82.5%) developed fever; no baseline characteristic was associated with its development. Median time to fever onset was 25.5 h (range, 9.5–100 h) and median peak temperature was 39.0 °C (range, 38.1–40.5 °C). Not a single patient developed hemodynamic or respiratory compromise that required admission to the intensive care unit. Fever was not explained by infection in any case. Ninety-one percent of the febrile episodes resolved within 96 h of cyclophosphamide administration. No significant difference in overall survival, event-free survival, or graft versus host disease-free/relapse-free survival was found in the group of febrile individuals after peripheral blood stem cell infusion. Conclusion: Fever after peripheral blood stem cell infusion in this clinical setting was common; it usually subsides with cyclophosphamide administration. The development of fever was not associated with an adverse prognosis. Mención de responsabilidad : Marcos Arango, Juan F Combariza Referencia : Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):79-84. DOI (Digital Object Identifier) : 10.1016/j.hemonc.2017.03.001 PMID : 28390959 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1658-3876(17)30031-6 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4047 Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide [documento electrónico] / Marcos Arango Barrientos, ; Juan Felipe Combariza Vallejo, . - 2017.
Obra : Hematology/Oncology and Stem Cell Therapy
Idioma : Inglés (eng)
Palabras clave : Cyclophosphamide fever haploidentical hematopoietic stem cell transplantation peripheral blood stem cell transplantation prognosis Resumen : Objective/background: Noninfection-related fever can occur after peripheral blood stem cell infusion in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. The objective of this study was to analyze the incidence of fever and characterize some clinical features of affected patients. Methods: A retrospective case-series study with 40 patients who received haploidentical hematopoietic stem cell transplantation was carried out. Results Thirty-three patients (82.5%) developed fever; no baseline characteristic was associated with its development. Median time to fever onset was 25.5 h (range, 9.5–100 h) and median peak temperature was 39.0 °C (range, 38.1–40.5 °C). Not a single patient developed hemodynamic or respiratory compromise that required admission to the intensive care unit. Fever was not explained by infection in any case. Ninety-one percent of the febrile episodes resolved within 96 h of cyclophosphamide administration. No significant difference in overall survival, event-free survival, or graft versus host disease-free/relapse-free survival was found in the group of febrile individuals after peripheral blood stem cell infusion. Conclusion: Fever after peripheral blood stem cell infusion in this clinical setting was common; it usually subsides with cyclophosphamide administration. The development of fever was not associated with an adverse prognosis. Mención de responsabilidad : Marcos Arango, Juan F Combariza Referencia : Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):79-84. DOI (Digital Object Identifier) : 10.1016/j.hemonc.2017.03.001 PMID : 28390959 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1658-3876(17)30031-6 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4047 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000645 AC-2017-034 Archivo digital Producción Científica Artículos científicos Disponible